J&J Delays European Rollout of Covid-19 Vaccine After Rare Clots

The pause in the rollout of Johnson & Johnson’s Covid-19 vaccine marks another setback for the world’s inoculation campaign, just as it was picking up speed in Europe and other regions where immunizations have lagged. The drugmaker suspended shots in Europe after U.S. officials paused vaccinations to review the cases of six women who suffered a type of brain blood clot similar to one reported as a rare side effect of the AstraZeneca Plc vaccine. Australia had already said it wouldn’t buy the J&J vaccine.